Live feed07:00:00·220dPRReleasevia QuantisnowFibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate CancerByQuantisnow·Wall Street's wire, on your screen.FGEN· FibroGen IncHealth Care
